Lilly Humatrope for short stature
Lilly's Humatrope (somatropin rDNA origin) supplemental NDA (19-604/S-033) for treatment of non-growth hormone deficiency short stature will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee on June 10. Studies have shown that growth hormone treatment in children with idiopathic short stature and normal GH levels may increase height by 4-6 cm over controls. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8:30 a.m...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.